Previously we showed that mononuclear cells from about half of human T-lymphotropic virus (HTLV)-seropositive persons exhibit spontaneous proliferation in vitro. We sought t o determine if proliferation was associated with other immunologic changes characteristic of HTLV infection. The parameters assessed were (1) percentages of lymphocytes expressing CD4 and/or CD25 (interleukin-2 receptor), (2) serum levels of soluble CD25, (3) serostatus for other viruses, (4) anti-HTLV antibody levels, and (5) HTLV type determined by polymerase chain reaction or serologic reactivity with typespecific peptides. The proliferation+ HTLV (PROL+) group, proliferation-HTLV (PROL-) group, and control group showed similar percentages of CD4' . CD25". and CD4+CD25+ lymphocytes; serum levels of soluble CD25 were also similar. Antibodies t o cytomegalovirus, hepatitis B core, and hepati-UMAN T-LYMPHOTROPIC viruses (HTLV) are H retroviruses that infect cells important in regulating immune responses.' HTLV-I is endemic to southern Japan, the Caribbean basin, and parts of Africa, and has been associated with the development of adult T-cell leukemia (ATL) and HTLV-associated myelopathy (also called tropical spastic paraparesis, abbreviated HAM/TSP).2-5 HTLV-I1 is closely related to HTLV-I, but disease associations are less Recent studies demonstrated that HTLV-I1 is endemic among intravenous drug users in the United States; accordingly, intravenous drug use represents the most common risk factor for HTLV infection among American blood Studies of immune alterations in ATL have shown that the malignant cell is usually CD4', and constitutively expresses high levels of CD25, the a-chain of the highaffinity interleukin-2 (IL-2) receptor."-" A soluble form of CD25 is also found at high levels in serum from ATL patient^.'^,'^ Increased levels of CD4+ cells and CD25+ cells, as well as serum soluble CD25, also characterize HAM/ TSP.'5*'6 Data on alterations of CD25 expression by lymphocytes from asymptomatic HTLV-infected carriers are conflicting and apparently reflect differences in the HTLV type endemic to the geographic area where the study was performed. In Japan, HTLV carriers (mainly type I) show small but statistically significant increases in the percentage of lymphocytes expressing CD25, whereas in Los Angeles, HTLV carriers (mainly type 11) exhibit no significant changes in CD25 cell level^.'^^" In studies of immune alterations in HTLV-seropositive former blood donors from the Los Angeles area, we have tis C were present in similar proportions of PROL+ and PROLgroups. However, a significant association was found between spontaneous proliferation and anti-HTLV antibody levels; sera from 67% of PROL+ persons, but only 18% of PROL-persons, required dilution t o yield absorbance values within the linear range of the anti-HTLV antibody assay. In the PROL' group, persons whose sera required the most dilution had proliferative responses significantly higher than those whose sera required no dilution. The PROL' and PROLgroups were similar with regard t o the relative distribution of HTLV-I and HTLV-II infection. These findings indicate that HTLV-related spontaneous lymphocyte proliferation is re- found that spontaneous lymphoproliferation occurs in roughly 50% of infected individual^.'^ We sought to determine if the presence or absence of a spontaneous lymphoproliferative response was related to the occurrence of immune alterations associated with overt HTLV-related disease, such as increased CD4+ cell levels, CD25' cell levels, or serum soluble CD25 levels. We also tested the hypothesis that HTLV-associated spontaneous lymphoproliferation was coincident to infection with other viruses. Further, we examined the relationship of spontaneous proliferation to levels of anti-HTLV antibodies and the HTLV type responsible for infection. 
H retroviruses that infect cells important in regulating
immune responses.' HTLV-I is endemic to southern Japan, the Caribbean basin, and parts of Africa, and has been associated with the development of adult T-cell leukemia (ATL) and HTLV-associated myelopathy (also called tropical spastic paraparesis, abbreviated HAM/TSP).2-5 HTLV-I1 is closely related to HTLV-I, but disease associations are less Recent studies demonstrated that HTLV-I1 is endemic among intravenous drug users in the United States; accordingly, intravenous drug use represents the most common risk factor for HTLV infection among American blood Studies of immune alterations in ATL have shown that the malignant cell is usually CD4', and constitutively expresses high levels of CD25, the a-chain of the highaffinity interleukin-2 (IL-2) receptor."-" A soluble form of CD25 is also found at high levels in serum from ATL patient^.'^,'^ Increased levels of CD4+ cells and CD25+ cells, as well as serum soluble CD25, also characterize HAM/ TSP.'5*'6 Data on alterations of CD25 expression by lymphocytes from asymptomatic HTLV-infected carriers are conflicting and apparently reflect differences in the HTLV type endemic to the geographic area where the study was performed. In Japan, HTLV carriers (mainly type I) show small but statistically significant increases in the percentage of lymphocytes expressing CD25, whereas in Los Angeles, HTLV carriers (mainly type 11) exhibit no significant changes in CD25 cell level^.'^^"
A second immune cell alteration characterizing HTLV infection is spontaneous lymphocyte proliferation during in vitro culture of mononuclear cells. Three reports's,20,21 indicate that cells from essentially all (31 of 32) HAM/TSP patients tested exhibited spontaneous proliferation; in contrast, cells from ATL patients did not show spontaneous proliferation. 21 Further, three studies have demonstrated spontaneous lymphoproliferation in asymptomatic HTLVseropositive person^.'^^^'^^^ In studies of immune alterations in HTLV-seropositive former blood donors from the Los Angeles area, we have tis C were present in similar proportions of PROL+ and PROLgroups. However, a significant association was found between spontaneous proliferation and anti-HTLV antibody levels; sera from 67% of PROL+ persons, but only 18% of PROL-persons, required dilution t o yield absorbance values within the linear range of the anti-HTLV antibody assay. In the PROL' group, persons whose sera required the most dilution had proliferative responses significantly higher than those whose sera required no dilution. The PROL' and PROLgroups were similar with regard t o the relative distribution of HTLV-I and HTLV-II infection. These findings indicate that HTLV-related spontaneous lymphocyte proliferation is related t o levels of circulating anti-HTLV antibodies, and characterizes both HTLV-I and HTLV-II infection. found that spontaneous lymphoproliferation occurs in roughly 50% of infected individual^.'^ We sought to determine if the presence or absence of a spontaneous lymphoproliferative response was related to the occurrence of immune alterations associated with overt HTLV-related disease, such as increased CD4+ cell levels, CD25' cell levels, or serum soluble CD25 levels. We also tested the hypothesis that HTLV-associated spontaneous lymphoproliferation was coincident to infection with other viruses. Further, we examined the relationship of spontaneous proliferation to levels of anti-HTLV antibodies and the HTLV type responsible for infection. 
MATERIALS AND METHODS
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in RPMI culture medium supplemented with 100 U/mL penicillin, 100 @mL streptomycin, 2 mmol/L glutamine, and 10% pooled human serum. Cells were cultured in triplicate in flat-bottom microtiter wells (0.2 mL cell suspension per well) for 7 days at 37°C in 5% CO,. Each well then received 0.5 FCi 'H-thymidine (Research Products International, Walkersville, MD) and incubation was continued for an additional 4 hours. Cells were then harvested onto glass fiber strips and counted for radioactivity.
To determine if spontaneous proliferation merely reflected better in vitro survival of lymphocytes from HTLV-seropositive persons compared with controls, cells cultured for 7 days were retrieved from microtiter wells, washed, and adjusted to 500,000 viable lymphocytes/mL in fresh culture medii" This suspension was placed in microtiter wells (100,000 cells/well) and 'Hthymidine incorporation assessed as described.
The percentages of lymphocytes expressing CD4 and/or CD25 were measured for 40 HTLVseropositive persons and 20 controls.26 Whole blood (50 FL) collected in EDTA tubes was placed in each of four polystyrene 12 x 75 mm tubes containing 0.1 mL of phosphate-buffered saline with 1% newborn calf serum (PBS-NCS) and monoclonal antibodies (Becton Dickinson Immunocytometry Systems, San Jose, CA) according to the following scheme: tube 1 = phycoerythrin (PE). tagged nonspecific mouse IgGI, fluorescein (F)-tagged nonspecific mouse IgG1; tube 2 = PE-anti-CD3; tube 3 = F-anti-CD3; tube 4 = PE-anti-CD25, F-anti-CD4. Following incubation at 4°C for 30 minutes, each tube received 2 mL of lysing agent (0.15 molL ammonium chloride) and was incubated for 10 minutes at room temperature. The cells were then washed in PBS-NCS and resuspended in 0.5 mL of the same buffer.
Cell fluorescence was analyzed using a FACScan brand flow cytometer (Becton Dickinson Immunocytometry Systems). Following the establishment of a lymphocyte gate, fluorescence gains were optimized using the cells in tube 1. Fluorescent compensation was then adjusted using the combined contents of tubes 2 and 3. Data for 10,000 ungated events were then collected from tube 1, the tube 2 + 3 combination, and tube 4; lymphocyte fluorescence was then analyzed using FACScan research software. Quadrants were set so that background fluorescence, as assessed using the cells in tube 1, was less than 2%.
Serum levels of soluble CD25 were measured for 52 HTLV-seropositive and 34 control samples using a double-epitope enzyme immunoassay (AMAC, Inc, Westbrook, ME). Absorbance values were converted to picomole values by interpolation from a standard curve.
Antibodies recognizing cytomegalovirus (CMV) were assessed in serum from the 134 HTLV-seropositive donors using a qualitative latex agglutination assay (Becton Dickinson Microbiology Systems, Cockeysville, MD). Antibodies recognizing hepatitis B core (HBc) proteins were assessed in sera from 129 of the HTLV-seropositive donors using a competitive enzyme immunoassay (Abbott Laboratories, North Chicago, IL). Sera from 109 of the HTLV-seropositive donors were tested for antibodies recognizing hepatitis C virus (HCV) using an enzyme immunoassay (Ortho Diagnostics, Raritan, NJ).
Serum specimens from the HTLV-seropositive group (N = 134) were retested for anti-HTLV antibodies using a licensed enzyme immunoassay (Abbott Laboratories). The cutoff absorbance value was calculated following the manufacturer's instructions. The signalkutoff ratio (SCR) was the quotient obtained by dividing the absorbance value for a given serum sample by the cutoff value. Specimens with absorbance values greater than 2.0 were diluted 1:3, 1:9, 1:27, and 131 in HTLV-negative human serum and tested again.
Serum samples from all 134 CD4 and CD25 cell levels.
Serum soluble CD25 assay.
Detection of antibodies to other viruses.
Screening immunoassay for anti-HTLV antibodies.
Determination of HTLV type.
HTLV-seropositive study subjects and six seronegative controls were tested for antibodies to HTLV-I or -11 using a series of synthetic peptide-coated polystyrene beads in a solid-phase enzyme immunoassay. Each peptide represented an area of 20 to 30 amino acids from HTLV envelope or core regions.*' If the HTLV type of HTLV-seropositive samples could not be determined in the synthetic peptide assay, frozen mononuclear cells, if available, were thawed and further characterized by polymerase chain reaction (PCR) as previously described.8 Differences among proportions were analyzed for significance using the x2 test. Group means were compared using the Mann Whitney U-test. Significance was defined as P < .05.
Statistics.
RESULTS
Shown in Fig 1 are proliferative responses of mononuclear cells for 20
HTLV-seronegative controls and 40 consecutively tested HTLV-seropositive former blood donors. Based on the distribution of proliferative responses in the control group, proliferative responses in the HTLV-seropositive group were scored as proliferation-positive (PROL' ) if greater than 2,000 cpm, and proliferation-negative (PROL-) if 12,000 cpm. Thus, in this group of 40 HTLV-seropositive samples, equal proportions (50%) were PROL' and PROL-. Cells from a total of 134 HTLV-seropositive individuals were tested for spontaneous lymphoproliferation; 63 (47%) were PROLt and 71 (53%) were PROL-.
PROLt cultures did not merely reflect better in vitro survival of lymphocytes from HTLV-seropositive individuals, compared with control individuals (Table 1) . DNA synthesis values for day 7 control cell cultures adjusted to 100,000 viable cells per well (viable cell assay results, Table  1 ) were almost identical to DNA synthesis values of unadjusted cultures (routine assay results, Table 1 ). Similarly, the proliferative status (PROL' or PROL-) of cultures of cells from HTLV-seropositive persons was the same in adjusted and unadjusted cultures.
Spontaneous lymphocyte proliferation. For 
Lymphocyte CD4 and CD25 expression. The percentages of lymphocytes expressing CD4 and/or CD25 were measured by flow cytometry in a subgroup of 40 HTLVseropositive persons (20 PROL', 20 PROL-) and 20 controls. In all three study groups, the mean percentage of lymphocytes with the indicated phenotype were as follows: CD25TD4-= 8; CD25'CD4' = 21 or 22; CD25-CD4' = 24 or 25. No significant differences were found when comparing the PROL' and PROL-groups, or when comparing each of these groups with the control group.
Absolute lymphocyte counts were available for all but one of the PROL+ and one of the PROL-individuals; the mean values were not significantly different (2,449 2 872 lymphocytes/pL for PROL+, 2,452 2 1,050 for PROL-). Further, the proportions of each group with atypical lymphocytes detectable by microscopic examination of differential slides were not significantly different (13 of 62 (21%) of PROL+, 14 of 70 (20%) of PROL-).
Serum levels of soluble CD25 were measured in 52 of the HTLV-seropositive persons (26 PROL', 26 PROL-) and 34 controls. The mean values (pmol/L) 2 1 standard deviation were 59 2 34 for the PROL' group, 72 f 64 for the PROL-group, and 65 f 25 for the control group. No significant differences were observed when comparing any combination of two groups.
The proportions of PROL-and PROL+ groups with antibodies to CMV, HBc, or HCV were not significantly different. These observed Soluble CD2.5 levels in serum.
C m HBc, and HCV serostatus.
proportions were as follows: CMV' = 72% of PROL-, 81% of PROL'; HBc' = 21% of PROL-, 21% of PROL'; HCV' = 22% of PROL-, 16% of PROL'.
All 134 serum specimens from HTLV-seropositive persons were retested for anti-HTLV antibodies using a licensed enzyme immunoassay (Abbott). As shown in Table 2 , a significantly higher proportion of serum samples from the PROL-group exhibited absorbance values less than 2.0 with SCR less than 3.0, compared with samples from the PROL' group. This difference was also reflected in the finding that the proportion of specimens with absorbance values above the upper limit of the assay (ie, > 2.0) was significantly higher in the PROL+ group than the PROL-group (line 4, Table  2 ). When serial threefold dilutions of these serum samples with absorbance values greater than 2 were retested, a significantly higher proportion of those from the PROLgroup, compared with the PROL' group, exhibited absorbance values on scale (<2) at a 1:3 dilution (line 5, Table  2 ). Thus, circulating anti-HTLV antibody levels were generally higher in the PROL' group than the PROL-group.
Within the PROL' group, there was a trend toward higher spontaneous proliferative responses in association with higher anti-HTLV antibody levels. As shown in Fig 2, proliferative responses were significantly higher in the subgroup whose sera had to be diluted 1:81 to obtain on-scale absorbance values, compared with the subgroup whose sera required no dilution.
Determination ofHTLVfype. Serum from the 134 HTLVseropositive study subjects (63 PROL' and 71 PROL-) were tested for reactivity to synthetic peptides specific for HTLV-I or HTLV-11. By this method, 121 of the 134 specimens (90%) were identified as HTLV-I or HTLV-I1 (Table 3) . As an internal positive control for the peptide assay, 19 of the 134 sera were from individuals previously typed by PCR as HTLV-11, and 17 of the 19 were identified as HTLV-I1 by the peptide assay; two were negative by the peptide assay. Similarly, six serum samples from HTLV-I' persons, as determined previously by PCR, were all typed as HTLV-I by the peptide assay. All of six seronegative control sera gave negative results in the peptide assay.
Frozen cells were available from 11 of the remaining 13 untyped HTLV-seropositive specimens, and these were subjected to PCR analysis to determine the HTLV type;
Anti-HTLV screening assay. For
DISCUSSION
Our findings show that mononuclear cells from roughly half of a large group of asymptomatic HTLV-seropositive donors from the LQS Angeles area exhibit spontaneous lymphocyte proliferation when cultured in vitro for 7 days, confirming our previous findings for a smaller group of HTLV-seropositive individuals." Two other group^'^^^" have reported spontaneous lymphoproliferation in asymptomatic HTLV-seropositive persons from Japan and the Caribbean (HTLV-I endemic areas). However, in these studies only mean values for proliferative responses were presented; no mention was made of the proportion of individuals in the carrier groups exhibiting responses within the normal range.
The mechanism responsible for HTLV-related spontaneous lymphocyte proliferation remains unclear. Studies by Gazzolo et a1 and Duc Dodon et alw32y have shown that HTLV-I envelope glycoproteins are mitogenic for normal human T cells. The time course of this response and phenotype of responding cells are similar to the spontaneous lymphoproliferative responses described here.3" We and others'-21 thus postulate that HTLV-related spontaneous lymphocyte proliferation reflects a response of lymphocytes to an intrinsic mitogenic or transactivating factor produced in association with HTLV infection (HTLV envelope peptides or Tax?). Studies are currently underway to identify the cellular source of this putative factor and to characterize the cell-cell interactions regulating the response.
We sought to determine if the presence or absence of a spontaneous proliferative response was related to other immunologic changes characterizing overt HTLV infection. The assay system used to measure CD4iCD25 expression (PE-anti-CD25 staining measured with a FACScan brand flow cytometer) has been shown to be much more sensitive than other assay systems,26 thus yielding %CD25' lymphocyte values greater than previously thought. In support of our earlier findings for HTLV-seropositive donors not stratified by spontaneous proliferation results," levels of lymphocytes expressing CD4 and/or CD25 were normal in both the PROL' and PROL-HTLV groups. Likewise, serum levels of soluble CD25 were normal in these two groups; this finding is consistent with those of Yasuda et al,13 who found normal soluble CD25 levels in asymptomatic HTLV-I carriers.
Because the prevalence of spontaneous lymphocyte proliferation in HTLV-infected carriers (about 50%) was similar to the prevalence of anti-CMV antibodies in the general blood donor population:' we asked if coincident CMV infection was associated with spontaneous proliferation. The data demonstrated that anti-CMV antibodies were present in most of the HTLV-seropositive persons, regardless of proliferation status. Similarly, no significant associations were observed between proliferation status and the prevalence of antibodies recognizing HBC or HCV. Thus, coincident infection by these viruses did not appear one was identified as HTLV-I, seven were identified as HTLV-I1 (Table 3) , and three were PCR negative. Thus, by a combination of synthetic peptide and PCR analyses, HTLV type was determined for 129 of the 134 (96.3%) HTLV-seropositive study subjects.
As summarized in Table 3 Likewise, the distributions of HTLV-I versus HTLV-I1 infection within the PROL' and PROL-groups were similar. Thus, spontaneous lymphocyte proliferation occurred in association with both HTLV-I and HTLV-I1 infection. Further, there was no stratification of proliferative responses in relation to HTLV type; the mean proliferative response for the 13 HTLV-I PROL' persons (28,349 cpm ? 18,866) was not significantly different from the mean value for the 48 HTLV-I1 PROL' persons (23,998 cpm ? 29,740). When assessing the relationship between spontaneous proliferation and circulating anti-HTLV antibodies, we documented a highly significant association. Whereas most persons in the PROL' group had a circulating anti-HTLV antibody concentration higher than that detected in the range of linearity in the Abbott screening assay, most persons in the PROL-group did not. Further, PROL' persons with very high anti-HTLV antibody levels exhibited higher spontaneous lymphoproliferative responses than PROL' persons with lower antibody levels. Thus, higher levels of circulating anti-HTLV antibodies were associated with HTLV-related spontaneous lymphoproliferation. This association observed for asymptomatic HTLV carriers is consistent with data published by Itoyama et alZo for HAM/TSP patients; all 14 HAh4iTSP patients had very high levels of HTLV-I antibodies, and lymphocytes from all 14 patients showed spontaneous proliferation.
The conditions responsible for the association between levels of circulating anti-HTLV antibodies and spontaneous proliferation remain unknown. High levels of circulating anti-HTLV antibodies are generally associated with a higher frequency of HTLV-infected cells, as judged by levels of signal generated in PCR analysis (Dr Helen Lee, unpublished observations). Thus, high levels of anti-HTLV antibodies may reflect a greater viral load. Our data showing a significant association between anti-HTLV antibody levels and spontaneous proliferation thus suggest that the presence or absence of spontaneous proliferation also reflects differences in viral load. In support of this hypothesis, about 10% of mononuclear cells from W S P patients contain HTLV-I proviral DNA,32 and lymphocytes from essentially all HAMiTSP patients appear to exhibit spontaneous p r~l i f e r a t i o n . '~~~~~~~ In contrast, only 0.1% to 2% of lymphocytes from asymptomatic HTLV-I carriers contain proviral DNA:' and we show here that lymphocytes from only half of asymptomatic carriers show spontaneous proliferation. A higher frequency of HTLV-infected cells would be expected to lead to greater levels of the putative mitogenic factor responsible for cell activation.
An important finding arising from the results of the type determination assays is that a proliferative response was observed in similar proportions of HTLV-I+ and HTLV-11' individuals. Thus, spontaneous proliferation was clearly not limited to a specific HTLV type causing infection. A recent abstract by Blattner et a1 presented similar findings.33 If future studies identify a link between spontaneous proliferation and clinical progression of HTLV-associated disease, then disease development should be expected in HTLV-11, as well as HTLV-I, infection.
